{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-132302","form_type":"8-K","ticker":"JANX","cik":"0001817713","company_name":"Janux Therapeutics, Inc.","filed_at":"2024-12-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.800574+00:00","generated_at":"2026-05-29T11:39:35.156215+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Janux reports positive interim JANX007 data; selects doses for Phase 1b expansion in mCRPC","bullets":["100% of 16 patients achieved PSA50 declines; 63% PSA90; 31% PSA99 declines.","75% maintained PSA50 and 50% maintained PSA90 at ≥12 weeks.","50% ORR (4/8 RECIST-evaluable patients) with confirmed/unconfirmed partial responses.","CRS and TRAEs primarily cycle 1, grade 1-2; MTD not yet reached.","Two once-weekly step dose regimens identified for Phase 1b in pre-PLUVICTO 2L/3L patients."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-132302","json":"https://secwatch.observer/filing/0000950170-24-132302.json","markdown":"https://secwatch.observer/filing/0000950170-24-132302.md","text":"https://secwatch.observer/filing/0000950170-24-132302.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1817713/000095017024132302/0000950170-24-132302-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1817713/000095017024132302/janx-20241202.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-29T11:39:35.156215+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}